Ablynx and Algeta Enter Into a Research Collaboration to

Ablynx and Algeta Enter Into a Research Collaboration to Evaluate the
Potential of Novel Alpha-Pharmaceuticals Comprising Thorium-277
Conjugated to Tumour-Targeting Nanobodies 
GHENT, BELGIUM and OSLO, NORWAY -- (Marketwire) -- 11/21/12 -- 
Ablynx (EURONEXT  BRUSSELS: ABLX) and Algeta ASA (OSE: ALGETA)
announce a research collaboration to evaluate a novel Targeted
Thorium Conjugate (TTC) based on combining Algeta's proprietary
thorium-227 alpha-pharmaceutical payload with Nanobodies(R) generated
using Ablynx's proprietary technology platform. 
Under the terms of the collaboration, Ablynx will provide access to
novel Nanobodies against a specific, undisclosed target and Algeta
will provide access to chelation and conjugation technologies, as
well as to its alpha-emitter
thorium-227. Both companies will
contribute resources towards the collaboration, which is expected to
last for up to a year initially with the option for extension
thereafter. No further terms have been disclosed. 
Andreas Menrad, Chief Scientific Officer of Ablynx, said:
 "We are
very pleased to be working with Algeta to discover and develop novel
cancer therapeutics based on both companies' proprietary
technologies. Our Nanobodies have the potential to selectively and
efficiently deliver Algeta's thorium-227 to the site of the tumour.
We are very excited about combining our unique and powerful
technology with Algeta's leading payload expertise to search for
breakthrough opportunities in oncology." 
Thomas Ramdahl, Executive Vice President and Chief Technology Officer
of Algeta, said:
 "The collaboration with Ablynx, the fifth TTC
programme to be disclosed by Algeta, is designed to evaluate the
potential of a Nanobody to act as the targeting molecule for the
alpha-pharmaceutical payload, thorium-227. This payload has the
potential to provide higher potency and more effective delivery over
other therapeutic payloads, with the further advantage that there are
no known cellular resistance mechanisms to the cell killing
properties of alpha particles." 
About Ablynx
 Ablynx is a biopharmaceutical company engaged in the
discovery and development of Nanobodies(R), a novel class of
therapeutic proteins based on  single-domain antibody fragments, for
a range of serious human diseases, including in
flammation,
haematology, oncology and pulmonary disease. Today, the Company has
approximately 25 programmes in the pipeline and seven Nanobodies at
clinical development stage. Ablynx has ongoing research
collaborations and significant partnerships with major pharmaceutical
companies including Boehringer Ingelheim, Merck KGaA, Novartis and
Merck & Co. The Company is headquartered in Ghent, Belgium. More
information can be found on www.ablynx.com. 
About the Ablynx Nanobody platform
 Nanobodies are antibody-derived
therapeutic proteins that contain the unique structural and
functional properties of naturally-occurring heavy-chain antibodies.
The Nanobody technology was originally developed following the
discovery that camelidae (camels and llamas) possess fully functional
antibodies that lack light chains. These heavy-chain antibodies
contain a single variable domain (VHH) and two constant domains (CH2
and CH3). Importantly, the cloned and isolated VHH domain is a
perfectly stable polypeptide harbouring the full antigen-binding
capacity of the original heavy-chain antibody. These newly discovered
VHH domains with their unique structural and functional properties
form the basis of a new generation of therapeutic antibodies which
Ablynx has named Nanobodies. 
About Algeta
 Algeta is a company focused on developing novel
targeted therapies for patients with cancer based on its
alpha-pharmaceutical platform. The Company is headquartered in Oslo,
Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge,
MA performing commercial marketing operations in the US. Algeta is
listed on the Oslo Stock Exchange (Ticker: ALGETA). For more
information please visit www.algeta.com. 
About the Algeta TTC Platform
 Algeta is evaluating the potential
utility of alpha-particle emitting elements in the treatment of
cancer. Previous studies[1] have indicated that such elements may
have value in treating cancers by causing double-strand DNA breaks
that trigger cell death, and have also shown that the effects of
alpha-emission are highly localised as a result of the very short
range of the alpha particle (2-10 cell diameters). Thorium-227 is one
alpha-particle emitting element (radionuclide) that has been selected
by Algeta for further investigation. By linking thorium-227 to
cancer-targeting molecules such as monoclonal antibodies, Algeta
believes it may be possible to develop a pipeline of targeted
alpha-pharmaceuticals, termed Targeted Thorium Conjugates, or TTCs.
The TTC platform is at an early research phase in development. Algeta
intends to evaluate TTCs in a broad range of cancer types to
determine whether the TTC platform could offer advantages over naked
(un-armed) antibodies or antibody-drug conjugate technologies that
use cytotoxic drugs (rather than alpha-emitting elements) as
payloads. Such advantages could include increased potency, a more
localised tumouricidal effect and the potential to address drug
resistance by virtue of the physical action of the alpha particles. 
[1] Hall (1994) Radiobiology for the Radiologist (Lippincott,
Philadelphia) 
press release in pdf : http://hugin.info/137912/R/1659601/537304.pdf 
For more information, please contact
Ablynx:
Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / 
+32 (0)473 39 50 68
e:  edwin.moses@ablynx.com 
Marieke Vermeersch
Associate Director Investor Relations
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX 
M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t:   +44 207 920 2330
e:  ablynx@mcomgroup.com 
Algeta:
Mike Booth
Communications & Corporate Affairs
+47 2202 4510
ir@algeta.com 
Kari Watson
MacDougall Biomedical Communications
+1 781 235 3060
kwatson@macbiocom.com 
Media enquiries:
Mark Swallow
Citigate Dewe Rogerson
+44 207 638 9571
mark.swallow@citigatedr.co.uk 
US investor enquiries:
Tricia Swanson
The Trout Group
+1 646 378 2953
tswanson@troutgroup.com